GO-DS21 | Gene overdosage and comorbidities during the early lifetime in Down Syndrome 01-01-2020 - 30-06-2025 Show more information Organisation PERHA PHARMACEUTICALS SAS
DOWN-AUTONOMY | LCTB-21: A DYRK1A protein kinase inhibitor for treatment of cognitive decline in Down Syndrome. 01-06-2022 - 30-06-2026 Show more information Organisation PERHA PHARMACEUTICALS SAS